PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Agreement to Acquire Adelia Therapeutics
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, recently announced its entry into a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million) in an all-stock transaction. The transaction is subject to the satisfaction or waiver of customary conditions, including receipt of all applicable regulatory and NEO Exchange Inc. approvals. “We are thrilled to join forces with Adelia, as we see this transaction as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focus on creating novel…